These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 7790077)

  • 21. Increased resistance in BALB/c mice to reinfection with Candida albicans is due to immunoneutralization of a virulence-associated immunomodulatory protein.
    Tavares D; Ferreira P; Arala-Chaves M
    Microbiology (Reading); 2003 Feb; 149(Pt 2):333-339. PubMed ID: 12624195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticandidal immunity and vaginitis: novel opportunities for immune intervention.
    Cassone A; De Bernardis F; Santoni G
    Infect Immun; 2007 Oct; 75(10):4675-86. PubMed ID: 17562759
    [No Abstract]   [Full Text] [Related]  

  • 23. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies.
    Polonelli L; De Bernardis F; Conti S; Boccanera M; Gerloni M; Morace G; Magliani W; Chezzi C; Cassone A
    J Immunol; 1994 Mar; 152(6):3175-82. PubMed ID: 8144911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secretory Aspartyl Proteinases Cause Vaginitis and Can Mediate Vaginitis Caused by Candida albicans in Mice.
    Pericolini E; Gabrielli E; Amacker M; Kasper L; Roselletti E; Luciano E; Sabbatini S; Kaeser M; Moser C; Hube B; Vecchiarelli A; Cassone A
    mBio; 2015 Jun; 6(3):e00724. PubMed ID: 26037125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique.
    Pietrella D; Rachini A; Torosantucci A; Chiani P; Brown AJ; Bistoni F; Costantino P; Mosci P; d'Enfert C; Rappuoli R; Cassone A; Vecchiarelli A
    Vaccine; 2010 Feb; 28(7):1717-25. PubMed ID: 20038431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defining criteria for anti-mannan antibodies to protect against candidiasis.
    Cutler JE
    Curr Mol Med; 2005 Jun; 5(4):383-92. PubMed ID: 15977994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-Saccharomyces cerevisiae mannan antibodies (ASCA) of Crohn's patients crossreact with mannan from other yeast strains, and murine ASCA IgM can be experimentally induced with Candida albicans.
    Schaffer T; Müller S; Flogerzi B; Seibold-Schmid B; Schoepfer AM; Seibold F
    Inflamm Bowel Dis; 2007 Nov; 13(11):1339-46. PubMed ID: 17636567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibodies to Candida albicans in human cervicovaginal secretions.
    Milne JD; Warnock DW
    Br J Vener Dis; 1977 Dec; 53(6):375-8. PubMed ID: 342069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of preinduced Candida-specific systemic cell-mediated immunity on experimental vaginal candidiasis.
    Fidel PL; Lynch ME; Sobel JD
    Infect Immun; 1994 Mar; 62(3):1032-8. PubMed ID: 8112837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of anti-Candida albicans IgE antibodies in vaginal washes from patients with acute vulvovaginal candidiasis.
    Regúlez P; García Fernández JF; Moragues MD; Schneider J; Quindós G; Pontón J
    Gynecol Obstet Invest; 1994; 37(2):110-4. PubMed ID: 8150365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody response that protects against disseminated candidiasis.
    Han Y; Cutler JE
    Infect Immun; 1995 Jul; 63(7):2714-9. PubMed ID: 7790089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel glyco-conjugate vaccine against fungal pathogens.
    Torosantucci A; Bromuro C; Chiani P; De Bernardis F; Berti F; Galli C; Norelli F; Bellucci C; Polonelli L; Costantino P; Rappuoli R; Cassone A
    J Exp Med; 2005 Sep; 202(5):597-606. PubMed ID: 16147975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human natural yeast killer toxin-like candidacidal antibodies.
    Polonelli L; De Bernadis F; Conti S; Boccanera M; Magliani W; Gerloni M; Cantelli C; Cassone A
    J Immunol; 1996 Mar; 156(5):1880-5. PubMed ID: 8596040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Growth inhibition of Candida albicans by vaginal cells from naïve mice.
    Steele C; Ozenci H; Luo W; Scott M; Fidel PL
    Med Mycol; 1999 Aug; 37(4):251-9. PubMed ID: 10421860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nystatin enhances the immune response against Candida albicans and protects the ultrastructure of the vaginal epithelium in a rat model of vulvovaginal candidiasis.
    Zhang X; Li T; Chen X; Wang S; Liu Z
    BMC Microbiol; 2018 Oct; 18(1):166. PubMed ID: 30359236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis.
    Fidel PL; Lynch ME; Sobel JD
    Infect Immun; 1993 Oct; 61(10):4202-7. PubMed ID: 8406809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic basis for protection against experimental vaginal candidiasis by peripheral immunization.
    Mulero-Marchese RD; Blank KJ; Sieck TG
    J Infect Dis; 1998 Jul; 178(1):227-34. PubMed ID: 9652445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunoglobulin classes of human serum antibodies in vaginal candidiasis.
    Warnock DW; Milne JD; Fielding AM
    Mycopathologia; 1978 Aug; 63(3):173-5. PubMed ID: 357978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Demonstration of β-1,2 mannan structures expressed on the cell wall of Candida albicans yeast form but not on the hyphal form by using monoclonal antibodies].
    Aydın C; Ataoğlu H
    Mikrobiyol Bul; 2015 Jan; 49(1):66-76. PubMed ID: 25706732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetics of antibody responses to cell wall mannan and a major cytoplasmic antigen of Candida albicans in rabbits and humans.
    Jones JM
    J Lab Clin Med; 1980 Nov; 96(5):845-60. PubMed ID: 6999104
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.